RxDoctor Payments Data

Mark Taylor

Optometrist · Kaysville, UTNPI 1811992555

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Johnson & Johnson Vision Care, Inc. at 50.3% of the total.

$1,404in general payments, 2019–2025

Across 45 payments — averaging $31.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$707
  • Apellis Pharmaceuticals, Inc.$294
  • Bausch & Lomb Americas Inc.$134
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$79
  • Alcon$73
  • Sight Sciences, Inc.$63
  • plus $54 from 2 others
$145,687in research payments, 2019–2025

Across 22 payments — averaging $6622.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$146K

What the payments were for

  • Food & beverage$1,404100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,404 in reported general payments places this provider in the 65th percentile of 423 optometrist providers in Utah.

See all optometrist providers in Utah

Medicare billing

Part B allowed, 2024
$10,538
Medicare patients
74
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tobramycin-DexamethasoneTobramycin/Dexamethasone17$744
Latanoprost18$51

Paid to pharmacies, not to this prescriber.

Other optometrist in Kaysville

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →